Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
ScinoPharm Taiwan Ltd banner

ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 18.9 TWD 0.27% Market Closed
Market Cap: NT$14.9B
Write Note Create Alert Ask AI

Wall St Price Targets

Price Forecast
Based on 3 analysts

+16% Upside
from NT$18.9 today

Analyst Rating
No ratings yet

No rating

We don't have analyst ratings for ScinoPharm Taiwan Ltd yet.

ScinoPharm Taiwan Ltd Competitors:
Price Targets

Revenue
Forecast

-3% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
-3% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been -3%. The projected CAGR for the next 2 years is 10%.

What are analyst estimates?

Gross Profit
Forecast

-6% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
-6% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been -6%. The projected CAGR for the next 2 years is 15%.

What are analyst estimates?

Operating Income
Forecast

-17% / Year
Past Growth
96% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
-17% / Year
Past Growth
96% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been -17%. The projected CAGR for the next 2 years is 96%.

What are analyst estimates?

Pre-Tax Income
Forecast

-16% / Year
Past Growth
78% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
-16% / Year
Past Growth
78% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -16%. The projected CAGR for the next 2 years is 78%.

What are analyst estimates?

Net Income
Forecast

-15% / Year
Past Growth
66% / Year
Estimated Growth
Estimates Accuracy
-13%
Average Miss
-15% / Year
Past Growth
66% / Year
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been -15%. The projected CAGR for the next 2 years is 66%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ScinoPharm Taiwan Ltd's stock price target?
Price Target
21.93 TWD

According to Wall Street analysts, the average 1-year price target for ScinoPharm Taiwan Ltd is 21.93 TWD with a low forecast of 21.72 TWD and a high forecast of 22.58 TWD.

What is the Revenue forecast for ScinoPharm Taiwan Ltd?
Projected CAGR
10%

Over the last 13 years, the compound annual growth rate for Revenue has been -3%. The projected CAGR for the next 2 years is 10%.

What is the Gross Profit forecast for ScinoPharm Taiwan Ltd?
Projected CAGR
15%

Over the last 13 years, the compound annual growth rate for Gross Profit has been -6%. The projected CAGR for the next 2 years is 15%.

What is the Operating Income forecast for ScinoPharm Taiwan Ltd?
Projected CAGR
96%

Over the last 13 years, the compound annual growth rate for Operating Income has been -17%. The projected CAGR for the next 2 years is 96%.

What is the Pre-Tax Income forecast for ScinoPharm Taiwan Ltd?
Projected CAGR
78%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -16%. The projected CAGR for the next 2 years is 78%.

What is the Net Income forecast for ScinoPharm Taiwan Ltd?
Projected CAGR
66%

Over the last 13 years, the compound annual growth rate for Net Income has been -15%. The projected CAGR for the next 2 years is 66%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.